Izervay™ (avacincaptad pegol) – Updated dosing

- On February 12, 2025, Astellas announced the FDA approval of a label update for Izervay (avacincaptad pegol), **removing the limitation that it could only be used for up to 12 months**.
- Izervay is approved for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
- The approved label update was based on positive results from the GATHER2 study, which evaluated the efficacy and safety of Izervay through year 2.
    - In the GATHER2 study, Izervay continued to reduce the rate of GA lesion growth in patients with GA secondary to AMD through 2 years vs. sham. The treatment benefit with Izervay vs. sham was observed as early as 6 months, continued to increase over time through 2 years, and more than doubled over 2 years compared to year 1.
- The recommended dose of Izervay is 2 mg (0.1 mL of 20 mg/mL solution) administered by intravitreal injection to each affected eye once monthly (approximately every 28 ± 7 days).